Novo Nordisk gets European green light for liraglutide  

2009.07.08
The European Commission has granted marketing authorisation for Novo Nordisk's GLP-1 analogue liraglutide for the treatment of type 2 diabetes in adults
Danish healthcare giant Novo Nordisk has announced in a press release that the European Commission has granted marketing authorisation for the company's Glucagon-Like Peptide (GLP-1) analogue liraglutide for the treatment of type 2 diabetes in adults. The authorisation covers all 27 EU member states.
 
Liraglutide is the first once-daily GLP-1 treatment, and will be sold under the brand name Victoza in Europe. The marketing authorisation covers the use of liraglutide in combination with oral hypoglycemic agents.
 
"This is an important milestone for Novo Nordisk and for the treatment of type 2 diabetes," says Novo Nordisk's chief scientific offer Mads Krogsgaard Thomsen in the press release. "In clinical studies involving more than 6,500 people with type 2 diabetes, Victoza has been shown to have a significant blood glucose-lowering effect and lead to weight loss, while having a low risk of hypoglycaemia. On this background, we are convinced that Victoza is a valuable new treatment option for people with type 2 diabetes."
 
Novo Nordisk will launch liraglutide in the UK, Germany and Denmark during this summer, and in other European markets during H2 2009 and throughout 2010.
 
Link > Novo Nordisk              

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×